Compare TBPH & ERII Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TBPH | ERII |
|---|---|---|
| Founded | 2013 | 1992 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Industrial Machinery/Components |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 850.2M |
| IPO Year | 2013 | 2008 |
| Metric | TBPH | ERII |
|---|---|---|
| Price | $13.86 | $9.93 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 5 | 2 |
| Target Price | ★ $18.50 | $16.50 |
| AVG Volume (30 Days) | 782.6K | ★ 783.4K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 5.00 |
| EPS | ★ 0.88 | 0.42 |
| Revenue | $15,386,000.00 | ★ $134,987,000.00 |
| Revenue This Year | $70.90 | $17.21 |
| Revenue Next Year | N/A | $21.97 |
| P/E Ratio | ★ $15.75 | $23.64 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $7.90 | $9.59 |
| 52 Week High | $21.03 | $18.31 |
| Indicator | TBPH | ERII |
|---|---|---|
| Relative Strength Index (RSI) | 27.74 | 25.07 |
| Support Level | $13.41 | $9.59 |
| Resistance Level | $14.76 | $14.85 |
| Average True Range (ATR) | 0.58 | 0.49 |
| MACD | -0.08 | -0.08 |
| Stochastic Oscillator | 11.29 | 15.84 |
Theravance Biopharma Inc is a diversified biopharmaceutical company focused on the discovery, development, and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small-molecule drugs designed to meet patient needs. Its research is focused on the areas of inflammation and immunology. The firm applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. The company develops lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD).
Energy Recovery Inc is an engineering-driven technology company. It is engaged in engineering, designing, manufacturing and supplying solutions that make industrial processes more efficient and sustainable. The company operates in three segments, Water, Emerging Technologies and Corporate. It offers energy recovery devices (ERDs) and pumps as well as related products and services to the reverse osmosis desalination market. The company derives a majority of the revenue from the Water segment. Geographically, the company operates in the U.S. and other international countries.